An2 Therapeutics Inc (ANTX)

$1.27 0.00 (N/A)
Market Cap 37.95M
Revenue (ttm) 0.00
Net Income (ttm) -64.73M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 89,700
Avg Vol 565,756
Day's Range N/A - N/A
Shares Out 29.88M
Stochastic %K 23%
Beta 0.18
Analysts Hold
Price Target $2.67

Latest News on ANTX

AN2 Therapeutics to Participate at Upcoming Investor Conferences

Nov 14, 2024, 7:00 AM EST - 2 months ago

AN2 Therapeutics to Participate at Upcoming Investor Conferences

AN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry Pipeline

Nov 13, 2024, 4:00 PM EST - 2 months ago

AN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry Pipeline

AN2 Therapeutics Receives Continuation Grant to Discover Novel Boron Based Therapies for Tuberculosis (caused by Mycobacterium tuberculosis) and Malaria

Oct 17, 2024, 7:00 AM EDT - 3 months ago

AN2 Therapeutics Receives Continuation Grant to Discover Novel Boron Based Therapies for Tuberculosis (caused by Mycobacterium tuberculosis) and Malaria

AN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 28, 2024, 4:00 PM EDT - 5 months ago

AN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan

Aug 16, 2024, 7:00 AM EDT - 5 months ago

AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan

AN2 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business and Scientific Highlights

Aug 13, 2024, 4:01 PM EDT - 5 months ago

AN2 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business and Scientific Highlights

AN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex (MAC) Lung Disease

Aug 8, 2024, 4:30 PM EDT - 5 months ago

AN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex (MAC) Lung Disease

AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights

May 14, 2024, 4:01 PM EDT - 8 months ago

AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights

AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights

Mar 28, 2024, 4:10 PM EDT - 10 months ago

AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights

AN2 Therapeutics to pause lung disease study enrollment

Feb 12, 2024, 6:56 AM EST - 1 year ago

AN2 Therapeutics to pause lung disease study enrollment

AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease

Feb 12, 2024, 6:45 AM EST - 1 year ago

AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease

AN2 Therapeutics to Present at Oppenheimer Healthcare Life Sciences Conference

Jan 30, 2024, 4:10 PM EST - 1 year ago

AN2 Therapeutics to Present at Oppenheimer Healthcare Life Sciences Conference

AN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific Highlights

Nov 9, 2023, 4:05 PM EST - 1 year ago

AN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific Highlights

AN2 Therapeutics to Present at Upcoming Investor Conferences

Nov 6, 2023, 7:00 AM EST - 1 year ago

AN2 Therapeutics to Present at Upcoming Investor Conferences

AN2 Therapeutics Signs License Agreement with the University of Georgia Research Foundation to Develop Novel Boron-Based Therapy for Chagas Disease

Oct 18, 2023, 7:00 AM EDT - 1 year ago

AN2 Therapeutics Signs License Agreement with the University of Georgia Research Foundation to Develop Novel Boron-Based Therapy for Chagas Disease

AN2 Therapeutics to Present New Data for Epetraborole at IDWeek 2023

Oct 11, 2023, 12:01 AM EDT - 1 year ago

AN2 Therapeutics to Present New Data for Epetraborole at IDWeek 2023

AN2 Therapeutics Signs Grant Agreement to Discover Novel, Boron Based Therapies for Tuberculosis and Malaria

Sep 26, 2023, 7:00 AM EDT - 1 year ago

AN2 Therapeutics Signs Grant Agreement to Discover Novel, Boron Based Therapies for Tuberculosis and Malaria

AN2 Therapeutics commences Phase 3 Part of Phase 2/3 Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium complex (MAC) Lung Disease

Sep 13, 2023, 7:00 AM EDT - 1 year ago

AN2 Therapeutics commences Phase 3 Part of Phase 2/3 Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium complex (MAC) Lung Disease

AN2 Therapeutics Announces Pricing of $70.0 Million Underwritten Offering of Common Stock

Aug 15, 2023, 10:42 PM EDT - 1 year ago

AN2 Therapeutics Announces Pricing of $70.0 Million Underwritten Offering of Common Stock

AN2 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights

Aug 10, 2023, 4:10 PM EDT - 1 year ago

AN2 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights

AN2 Therapeutics to Present at Jefferies Healthcare Conference

May 25, 2023, 4:10 PM EDT - 1 year ago

AN2 Therapeutics to Present at Jefferies Healthcare Conference

AN2 Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights

May 11, 2023, 4:10 PM EDT - 1 year ago

AN2 Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights

AN2 Therapeutics: Boron Chemistry For Infectious Diseases

May 5, 2023, 1:55 PM EDT - 1 year ago

AN2 Therapeutics: Boron Chemistry For Infectious Diseases

AN2 Therapeutics to Present at JMP Securities Life Sciences Conference

May 1, 2023, 7:00 AM EDT - 1 year ago

AN2 Therapeutics to Present at JMP Securities Life Sciences Conference

AN2 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights

Mar 29, 2023, 4:01 PM EDT - 1 year ago

AN2 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights

AN2 Therapeutics to Participate in Upcoming Investor Conferences

Feb 28, 2023, 4:10 PM EST - 2 years ago

AN2 Therapeutics to Participate in Upcoming Investor Conferences

AN2 Therapeutics to Present at SVB Securities Global Biopharma Conference

Jan 31, 2023, 4:10 PM EST - 2 years ago

AN2 Therapeutics to Present at SVB Securities Global Biopharma Conference

AN2 Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates

Nov 9, 2022, 4:05 PM EST - 2 years ago

AN2 Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates

AN2 Therapeutics to Present New Epetraborole Data at IDWeek 2022

Oct 19, 2022, 8:00 AM EDT - 2 years ago

AN2 Therapeutics to Present New Epetraborole Data at IDWeek 2022

AN2 Therapeutics Provides Update on Epetraborole Ex-U.S. Development Plan in Treatment-Refractory MAC Lung Disease

Oct 6, 2022, 7:00 AM EDT - 2 years ago

AN2 Therapeutics Provides Update on Epetraborole Ex-U.S. Development Plan in Treatment-Refractory MAC Lung Disease

NIH Awards Contract to AN2 Therapeutics Valued Up to $17.8 Million

Sep 29, 2022, 7:00 AM EDT - 2 years ago

NIH Awards Contract to AN2 Therapeutics Valued Up to $17.8 Million

AN2 Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference

Aug 29, 2022, 7:00 AM EDT - 2 years ago

AN2 Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference

AN2 Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates

Aug 11, 2022, 4:10 PM EDT - 2 years ago

AN2 Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates

AN2 Therapeutics Initiates Pivotal Phase 2/3 Trial Evaluating Epetraborole for Treatment-Refractory MAC Lung Disease

Jun 29, 2022, 7:00 AM EDT - 2 years ago

AN2 Therapeutics Initiates Pivotal Phase 2/3 Trial Evaluating Epetraborole for Treatment-Refractory MAC Lung Disease

AN2 Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates

May 10, 2022, 4:10 PM EDT - 2 years ago

AN2 Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates

AN2 Therapeutics Appoints Maggie FitzPatrick to Its Board of Directors

May 9, 2022, 7:00 AM EDT - 2 years ago

AN2 Therapeutics Appoints Maggie FitzPatrick to Its Board of Directors

U.S. IPO Weekly Recap: The IPO Market Remains Frozen In A 1 IPO Week

Mar 26, 2022, 2:55 AM EDT - 3 years ago

U.S. IPO Weekly Recap: The IPO Market Remains Frozen In A 1 IPO Week

RA Capital-Backed AN2 Therapeutics Hits NASDAQ, With IPO Price At $15

Mar 25, 2022, 3:23 PM EDT - 3 years ago

RA Capital-Backed AN2 Therapeutics Hits NASDAQ, With IPO Price At $15

AN2 Therapeutics Stock to List Today

Mar 25, 2022, 9:39 AM EDT - 3 years ago

AN2 Therapeutics Stock to List Today

AN2 Therapeutics Announces Pricing of Upsized Initial Public Offering

Mar 24, 2022, 10:32 PM EDT - 3 years ago

AN2 Therapeutics Announces Pricing of Upsized Initial Public Offering

IPO Update: AN2 Therapeutics Seeks $60 Million U.S. IPO

Mar 22, 2022, 4:36 AM EDT - 3 years ago

IPO Update: AN2 Therapeutics Seeks $60 Million U.S. IPO

AN2 Therapeutics Set for a March IPO

Mar 21, 2022, 5:16 PM EDT - 3 years ago

AN2 Therapeutics Set for a March IPO